References to primary literature
- References of special interest have been highlighted as: = of interest = of considerable interest
- ROIZMAN B: Herpes virldae A Brief Introduction. In: Virology, 2nd edition, Fields BN, KNIFE DM, CHANOCK RM, HIRSCH MS, MELNICK JL, MONATH TP, ROIZMAN B, (Eds.), Raven Press, New York. pp 1787-1793.
- WATSON PN, EVANS RJ: Fos therpetic neuralgia: a review. Arch. Neurol. (1986) 43:836–840.
- DUNKLE LM, ARVIN AM, WHITLEY RJ, ROTBART HA, FEDER HM, FELDMAN S, GERSHON AA, LEVY ML, HAYDEN GF, MCGUIRT PV, HARRIS J, BALFOUR HH: A controlled trial of acydovir for chickenpox in normal children. N. Engl. J. Med. (1991) 325:1539–1544.
- BALFOUR HH, ROTBART HA, FELDMAN S, DUNKLE LM, FEDER HM, PROBER CG, HAYDEN GF, STEINBERG S, \WHITLEY RJ, GOLDBERG L, MCGUIRT PV, and the Collabo-rative Acyclovir Varicella Study Group: Acyclovir treatment of varicella in otherwise healthy adolescents. J. Pediatr. (1992) 120:627–633.
- FDC Reports, "The Pink Sheet" (1992) 3:2.
- BLUM MR, WELLER S, DE MIRANDA P, CEDERBERG D, BURNE I JET, SMILEY L: 31st ICAAC (1991) Abst. 763.
- BEAUCHAMP LM, ORR GF, DE MIRANDA P, BURNETTE T,KRENITSKY TA: Amino add ester prodrugs of acyclovir. Antiviral Chem. Chemother. (1992) 3:157–164.
- FOWLES SE, WINTON CF, PRINCE WI', PIERCE DM: 31stICAAC (1991) Abst. 764.
- OLSEN S, STEWART M, DEVAULT A, WEAVER J, SUGERMANA, TU j, HEDDEN B, SHOSTACK G, RIELLY-GALTVIN K, SHERMAN j: 31st ICAAC (1991) Abst. 766.
- KRENITSKY TA, =LE JV, MILLER WH, MOORMAN AR,ORR GF, BEAUCHAMP L: Nucleotide analogue inhibitors of purine nucleoside phosphorylase. J. Biol. Chem. (1990) 265:3066–3069.
- BABA M, KONNO K, SHIGETA S, DE CLERCQ E: Inhibitoryeffects of selected antiviral compounds on newly iso-lated clinicalvaricella-zoster virus strains. Tohokuj. Exp. Med. (1986) 148:275–283.
- RAHIM SG, TEVIDI N, SELWAY J, DARBY G, COLLINS P, POWELL KL, PURIFOY DJM: 5-Allkynyl pyrimidine nu-cleosides as potent selective inhibitors of varicella-zos-ter virus.Antiviral Chem. Chemother. (1992) 3:293–297.
- A potent and selective series of compounds with minimal toxicity.
- WALL ME, WANI MC, COOK CE, PALMER KB, MCPHAIL AT,SIM GA: Plant antitumor agents. L The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotbeca acuminate. J. Amer. Chem. Soc. (1966) 88:3888–3890.
- ANDOH T, ISHII K, SUZUKI Y, IKEGAMI Y, KUSUNOKI Y,TAKEMOTO Y, OKADA K: Characterization of a mam-malian mutant with a camptothecin-resistant DNA topoisomerase I. Proc. Natl. Acad. Sci. U.S.A. (1987) 84:5565–5569.
- KJELDSEN E, BONVEN BJ, ANDOH T, ISHII K, OKADA K,BOLUND DL, WESTERGAARD 0: Characterization of a camptothecin-resistant human DNA topoisomerase L J. Biol. Chem. (1988) 263:3912–3916.
- HERTZBERG RP, CARANFA MJ, HOLDEN KG, JAKAS DR,GALLAGHER G, MATTERN MR, MONG S-M, BARTUS JO, JOHNSON RK, KINGSBURY WD: Modification of the hy-droxy lactone ring of camptothecin: Inhibition of mam-malian topoisomerase I and biological activity. J. Med. Chem. (1989) 32:715–720.
- GANDREAU P, PARADIS H, LANGELIER Y, BRAZEAU P: Synthesis and Inhibitory Potency of Peptides Corre-sponding to the Subunit 2 C-Terminal Region of Herpes Virus Ribonucleotide Reductases. J. Med. Chem. (1990) 33:723–730.
- Novel approacb to non-nucleoside antivirals. See patent 130 for further examples.